Related Experiment Video

Updated: Aug 21, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

[Pneumococcal conjugate vaccine in children]

J Lévy1, B Swennen

  • 1Service de Pédiatrie, CHU Saint-Pierre, Bruxelles.

Revue Medicale De Bruxelles
|November 2, 2004
PubMed

Insights

Pneumococcal conjugate vaccines effectively prevent invasive infections in children and reduce disease transmission. However, vaccine shortages and high costs may hinder widespread implementation in Belgium.

Area of Science:

  • Bacteriology and Immunology
  • Vaccine Development and Efficacy

Context:

  • Streptococcus pneumoniae is a leading cause of severe invasive infections in young children.
  • Infant immunogenicity challenges with purified polysaccharides necessitated conjugate vaccine development.

Purpose:

  • To evaluate the efficacy and impact of pneumococcal conjugate vaccines (PCVs) in pediatric populations.
  • To assess the role of PCVs in preventing invasive pneumococcal disease (IPD) and otitis media.

Summary:

  • A 7-valent PCV demonstrated 97% efficacy against vaccine-type IPD in US children.
  • PCVs offer protection against vaccine-type otitis media, though with limited global impact on total cases.
  • Large-scale PCV use significantly reduced IPD burden in vaccinated children and adult contacts.

Impact:

  • PCVs have shown substantial epidemiological impact on invasive pneumococcal disease burden.
  • Inclusion in Belgium's vaccination schedule highlights PCV importance.
  • Vaccine shortages and cost present challenges to optimal implementation and public health goals.

More Related Videos

Experimental Human Pneumococcal Carriage07:47

Experimental Human Pneumococcal Carriage

Published on: February 15, 2013

Homogeneous Glycoconjugate Produced by Combined Unnatural Amino Acid Incorporation and Click-Chemistry for Vaccine Purposes13:53

Homogeneous Glycoconjugate Produced by Combined Unnatural Amino Acid Incorporation and Click-Chemistry for Vaccine Purposes

Published on: December 19, 2020

Related Concept Videos

Streptococcal Pharyngitis01:27

Streptococcal Pharyngitis

Streptococcal pharyngitis, commonly known as “strep throat,” is an acute infection of the oropharyngeal tissues caused by the Gram‑positive Group A Streptococcus (Streptococcus pyogenes). Transmission occurs primarily through respiratory droplets expelled during coughing, sneezing, or talking.Mechanisms of Host Entry and Immune EvasionUpon entering the host, S. pyogenes adheres to the mucosal epithelial cells of the pharynx via surface proteins, notably lipoteichoic acid and the antiphagocytic...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...